• Uri Singfer, Dimitri Hemelsoet, Peter Vanlangenhove, Frederic Martens, Luc Verbeke, Dirk Van Roost, and Luc Defreyne.
• From the Faculty of Medicine and Health Sciences (U.S.), Department of Interventional Neuroradiology (P.V., L.D.), Department of Neurology (D.H.), and Department of Neurosurgery (D.V.R.), Ghent University Hospital, Belgium; and Departments of Neurosurgery (F.M.) and Radiotherapy (L.V.), Onze-Lieve-Vrouw Hospital, Aalst, Belgium.
• Stroke. 2017 Dec 1; 48 (12): 3393-3396.

Background And PurposeIn light of evidence from ARUBA (A Randomized Trial of Unruptured Brain Arteriovenous Malformations), neurovascular specialists had to reconsider deliberate treatment of unruptured brain arteriovenous malformations (uBAVMs). Our objective was to determine the outcomes of uBAVM treated with primary embolization using ethylene vinyl alcohol (ONYX).MethodsPatients with uBAVM who met the inclusion criteria of ARUBA and were treated with primary Onyx embolization were assigned to this retrospective study. The primary outcome was the modified Rankin Scale score. Secondary outcomes were stroke or death because of uBAVM or intervention and uBAVM obliteration.ResultsSixty-one patients (mean age, 38 years) were included. The median observation period was 60 months. Patients were treated by embolization alone (41.0%), embolization and radiosurgery (57.4%), or embolization and excision (1.6%). Occlusion was achieved in 44 of 57 patients with completed treatment (77.2%). Forty-seven patients (77.1%) had no clinical impairment at the end of observation (modified Rankin Scale score of <2). Twelve patients (19.7%) reached the outcome of stroke or death because of uBAVM or intervention. Treatment-related mortality was 6.6% (4 patients).ConclusionsIn uBAVM, Onyx embolization alone or combined with stereotactic radiosurgery achieves a high occlusion rate. Morbidity remains a challenge, even if it seems lower than in the ARUBA trial.© 2017 American Heart Association, Inc.

31 keywords...

hide…